Fundraising Fox
CEL SCI
NYSE: CVMVienna, US · Colorado corporation
Find your way into CEL SCI
Sign up to see every warm intro you have to CEL SCI
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CEL SCI team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CEL-SCI Corporation is a biotech company developing immunotherapies, particularly Multikine, which is advancing through FDA regulatory processes. The company is focused on cancer treatment and has progressed to Phase 3 clinical trials.
Founders & leadership
PB
Patricia B. PrichepExecutive
ET
Eyal TalorExecutiveChief Scientific Officer at CEL-SCI Corporation with over 25 years of experience in immunology-focused drug development. He holds a postdoctoral fellowship in clinical immunology from Johns Hopkins University and is a co-inventor on multiple patents.
Board
PY
Peter YoungBoard director
BB
Bruno BaillavoineBoard director
AG
Alexander G. EsterhazyBoard director
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 2 of 3 rounds · 2017–2018
▶$78KraisedJul 2018 · 4 investors · BiotechnologyRule 506(b)
▶$78KraisedJul 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter R. YoungDirector
- Robert WatsonDirector
- Geert KerstenExecutive Officer, Director
- Eyal TalorExecutive Officer
- John CiprianoExecutive Officer
- Bruno BailavoineDirector
- Patricia B. PrichepExecutive Officer
- Daniel H. ZimmermanExecutive Officer
- Offering amount
- $78K
- Amount sold
- $78K
- Minimum investment
- $10K
- Sales commissions
- $5.5K
- Placement agents
- H.C. Wainwright
- First sale
- Jul 2018
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$1.5MofferedJul 2017 · 6 investors · PharmaceuticalsRule 506(b)
▶$1.5MofferedJul 2017 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Patricia PrichepExecutive Officer
- Daniel ZimmermanExecutive Officer
- Alexander EsterhazyDirector
- Geert R. KerstenExecutive Officer
- Bruno BailavoineDirector
- John CiprianoExecutive Officer
- Peter YoungDirector
- Eyal TalorExecutive Officer
- Offering amount
- $1.5M
- Minimum investment
- $50K
- First sale
- Jun 2017
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$1MraisedFeb 2017 · 2 investors · PharmaceuticalsRule 506(b)
▶$1MraisedFeb 2017 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter R. YoungDirector
- Patricia B. PrichepExecutive Officer
- Eyal TalorExecutive Officer
- Geert R. KerstenExecutive Officer, Director
- Bruno BaillavoineDirector
- Daniel H. ZimmermanExecutive Officer
- Alexander G. EsterhazyDirector
- John CiprianoExecutive Officer
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $1K
- Sales commissions
- $70K
- Proceeds to insiders
- $142K
- First sale
- Feb 2017
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as CEL SCI.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $162.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $134.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $104.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2000 | $379.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2000 | — |
| Department of Health and Human Services | Phase I | 1998 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does CEL SCI do?
- CEL-SCI Corporation is a biotech company developing immunotherapies, particularly Multikine, which is advancing through FDA regulatory processes. The company is focused on cancer treatment and has progressed to Phase 3 clinical trials.
- How much funding has CEL SCI raised?
- CEL SCI has disclosed $1.1M raised across 2 of its 3 known rounds.
- Where is CEL SCI headquartered?
- CEL SCI is headquartered in Vienna, US.